CT1-3
CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2460738-32-1
- 分子式: C25H29NO3S2
- 分子量:455.63
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
9.07 μM
Compound: CT1-3
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| AGS | IC50 |
8.02 μM
Compound: CT1-3
|
Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| HepG2 | IC50 |
6.24 μM
Compound: CT1-3
|
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| HONE1 cell line | IC50 |
14.06 μM
Compound: CT1-3
|
Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| LoVo | IC50 |
5.1 μM
Compound: CT1-3
|
Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| MCF7 | IC50 |
12.72 μM
Compound: CT1-3
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| MDA-MB-231 | IC50 |
7.48 μM
Compound: CT1-3
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| NCI-H1299 | IC50 |
9.17 μM
Compound: CT1-3
|
Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| NCI-H1650 | IC50 |
6.92 μM
Compound: CT1-3
|
Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| NCI-H460 | IC50 |
6.15 μM
Compound: CT1-3
|
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| OVCAR-3 | IC50 |
5.34 μM
Compound: CT1-3
|
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| SGC-7901 | IC50 |
11.47 μM
Compound: CT1-3
|
Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| SW480 | IC50 |
6.07 μM
Compound: CT1-3
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
| U-251 | IC50 |
7.75 μM
Compound: CT1-3
|
Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 32416457] |
体外実験
CT1-3 has excellent inhibitory activity against multiple cancer cells with IC50 range of 5.10~14.06 μM in LOVO, A549, HepG2, MDA-MB-231 and HONE1, et al[1].
CT1-3 (10 μM; 24 h) notably increases ROS production in HCCs, significantly decreases mitochondrial membrane potential, and reduces Bcl-2 and XIAP levels and increases phospho-JNK and Bax levels[1].
CT1-3 (7.5 μM; 24 h) reduces the capacity of migration and invasion of HCCs, significantly promotes the expression level of E-cadherin (E-cad), and markedly decreases the pro-metastatic and pro-invasive protein Snail[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549, H460 and LOVO
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Notably increased ROS production, significantly decreased mitochondrial membrane potential, and reduced Bcl-2 and XIAP levels and increased phospho-JNK and Bax levels.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c-nu/nu mice (injected with A549, OVCAR3 and MDA-MB-231)[1]
-
Dosage:20 mg/kg
-
Administration:IP, for 28 days
-
Result:Significantly suppresses tumor growth and exhibited no hepatic and renal toxicity.
化学情報
-
CAS 番号 2460738-32-1
-
分子量 455.63
-
分子式 C25H29NO3S2
-
SMILES
OC1=CC=C(CC=C)C=C1C2=CC(CC=C)=CC=C2OCCS(CCCCN=C=S)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Nephrotoxicity Study
This protocol assesses nephrotoxicity by combining functional kidney injury readouts, urinary/tissue injury biomarkers, and renal histopathology. Serum creatinine and BUN reflect impaired kidney function, while KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, Oat5, urinary protein, glucose, and alkaline phosphatase have been used to detect tubular injury in cisplatin-, gentamicin-, and acetaminophen-induced nephrotoxicity models.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)